CNTB · Connect Biopharma Holdings Ltd
Price & Indicators
Up next
Latest filings
Connect Biopharma reported Phase 2 results for rademikibart in COPD: treatment failure fell 81%, moderate-to-severe exacerbations fell 85%, and ED visits or hospital admissions fell 100% through Week 4 versus placebo; it will seek FDA input on Phase 3.
Read the 8-KMetrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Phase 2 Seabreeze STAT Asthma Study enrolled participants | 160 | as of August 12, 2026 | — |
| Phase 2 Seabreeze STAT COPD Study enrolled participants | 159 | as of August 12, 2026 | — |
| Phase 2 Seabreeze STAT IV study participants (planned) | 40 | as of August 12, 2026 | — |
| Remaining milestone payments eligible under Simcere license agreement | 99M | as of August 12, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNTB
this stock
Connect Biopharma Holdings Ltd
|
$53.06M | -70.1% | -99.8% | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +5.7% | +20.8% | 20.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.39B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Sep 30, 2026
- This year
- 13
Connect Biopharma reported Phase 2 results for rademikibart in COPD: treatment failure fell 81%, moderate-to-severe exacerbations fell 85%, and ED visits or hospital admissions fell 100% through Week 4 versus placebo; it will seek FDA input on Phase 3.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNTB | -3.7% | -15.1% | -66.0% | -23.4% | -70.1% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -3.8% | -15.8% | -70.9% | -24.3% | -83.0% |